954|0|Public
25|$|Aspirin {{and other}} nonsteroidal {{anti-inflammatory}} drugs {{have been found}} to attenuate the diuresis and <b>natriuresis</b> induced by spironolactone therapy but not to affect its antihypertensive effect.|$|E
25|$|Due to its {{similarity}} to vasopressin, it {{can reduce the}} excretion of urine slightly. In several species, oxytocin can stimulate sodium excretion from the kidneys (<b>natriuresis),</b> and, in humans, high doses can result in low sodium levels (hyponatremia).|$|E
25|$|ACE inhibitors {{block the}} {{conversion}} of angiotensin I (AI) to angiotensin II (AII). They thereby lower arteriolar resistance and increase venous capacity; decrease cardiac output, cardiac index, stroke work, and volume; lower resistance in {{blood vessels in the}} kidneys; and lead to increased <b>natriuresis</b> (excretion of sodium in the urine).|$|E
25|$|Nesiritide, a {{recombinant}} form of B-natriuretic peptide, {{is indicated}} {{for use in}} patients with acute decompensated heart failure who have dyspnea at rest. Nesiritide promotes diuresis and <b>natriuresis,</b> thereby ameliorating volume overload. It is thought that, while BNP is elevated in heart failure, the peptide that is produced is actually dysfunctional or non-functional and thereby ineffective.|$|E
25|$|Doses of {{caffeine}} {{equivalent to the}} amount normally found in standard servings of tea, coffee and carbonated soft drinks appear to have no diuretic action. However, acute ingestion {{of caffeine}} in large doses (at least 250–300mg, equivalent to the amount found in 2–3 cups of coffee or 5–8 cups of tea) results in a short-term stimulation of urine output in individuals who have been deprived of caffeine {{for a period of}} days or weeks. This increase is due to both a diuresis (increase in water excretion) and a <b>natriuresis</b> (increase in saline excretion); it is mediated via proximal tubular adenosine receptor blockade. The acute increase in urinary output may increase the risk of dehydration. However, chronic users of caffeine develop a tolerance to this effect, and experience no increase in urinary output.|$|E
2500|$|Dopamine receptors {{are present}} along the nephron in the kidney, with {{proximal}} tubule epithelial cells showing the highest density. In rats, D1-like receptors are {{present on the}} juxtaglomerular apparatus and on renal tubules, while D2-like receptors are present on the glomeruli, zona glomerulosa cells of the adrenal cortex, renal tubules, and postganglionic sympathetic nerve terminals. Dopamine signaling affects [...] and <b>natriuresis.</b>|$|E
50|$|Natriuretic peptide {{refers to}} a peptide which induces <b>natriuresis,</b> the {{excretion}} of sodium by the kidneys.|$|E
50|$|Elevated {{levels of}} {{progesterone}} potently reduce the sodium-retaining activity of aldosterone, resulting in <b>natriuresis</b> {{and a reduction}} in extracellular fluid volume. Progesterone withdrawal, on the other hand, is associated with a temporary increase in sodium retention (reduced <b>natriuresis,</b> with an increase in extracellular fluid volume) due to the compensatory increase in aldosterone production, which combats the blockade of the mineralocorticoid receptor by the previously elevated level of progesterone.|$|E
50|$|Escape {{from the}} sodium-retaining effects of excess {{aldosterone}} (or other mineralocorticoids) in primary hyperaldosteronism, manifested by volume and/or pressure <b>natriuresis.</b>|$|E
50|$|High blood calcium causes <b>natriuresis</b> (increased sodium {{loss in the}} urine) {{and water}} diuresis, in part by its effect through the calcium-sensing {{receptor}} (CaSR).|$|E
50|$|It is also {{reported}} that this form of calcium increases renal plasma flow, diuresis, <b>natriuresis,</b> glomerular filtration rate, and prostaglandin E2 and F1-alpha levels.|$|E
50|$|Aspirin {{and other}} nonsteroidal {{anti-inflammatory}} drugs {{have been found}} to attenuate the diuresis and <b>natriuresis</b> induced by spironolactone therapy but not to affect its antihypertensive effect.|$|E
50|$|<b>Natriuresis</b> is {{the process}} of sodium {{excretion}} in the urine through the action of the kidneys. It is promoted by ventricular and atrial natriuretic peptides as well as calcitonin, and inhibited by chemicals such as aldosterone. <b>Natriuresis</b> lowers the concentration of sodium in the blood and also tends to lower blood volume because osmotic forces drag water out of the body's blood circulation and into the urine along with the sodium. Many diuretic drugs take advantage of this mechanism to treat medical conditions like hypernatremia and hypertension, which involve excess blood volume.|$|E
50|$|The {{physiologic}} {{actions of}} BNP {{are similar to}} those of ANP and include decrease in systemic vascular resistance and central venous pressure as well as an increase in <b>natriuresis.</b> The net effect of these peptides is a decrease in blood pressure due to the decrease in systemic vascular resistance and, thus, afterload. Additionally, the actions of both BNP and ANP result in a decrease in cardiac output due to an overall decrease in central venous pressure and preload as a result of the reduction in blood volume that follows <b>natriuresis</b> and diuresis.|$|E
50|$|It is {{localized}} in {{the kidney}} where {{it results in}} <b>natriuresis</b> upon binding to natriuretic peptides. However, it is found in even greater quantity in the lungs and adipocytes.|$|E
50|$|ETB1 mediates vasodilation, When endothelin binds to ETB1 receptors, {{this leads}} to the release of nitric oxide (also called endothelium-derived {{relaxing}} factor), <b>natriuresis</b> and diuresis (the production and elimination of urine) and mechanisms that lower blood pressure.|$|E
5000|$|Due to its {{similarity}} to vasopressin, it {{can reduce the}} excretion of urine slightly. In several species, oxytocin can stimulate sodium excretion from the kidneys (<b>natriuresis),</b> and, in humans, high doses can result in low sodium levels (hyponatremia).|$|E
50|$|Omapatrilat (INN, {{tentative}} {{trade name}} Vanlev) is an antihypertensive agent that inhibits both neprilysin (neutral endopeptidase, NEP) and angiotensin-converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting <b>natriuresis,</b> diuresis, vasodilation, and reductions in preload and ventricular remodeling.|$|E
50|$|The {{increase}} in urine flow rate decreases the contact time between fluid and the tubular epithelium, thus reducing sodium {{as well as}} water reabsorption. The resulting <b>natriuresis</b> is of lesser magnitude than the water diuresis, leading eventually to excessive water loss and hypernatremia.|$|E
50|$|Bradykinin is {{a potent}} endothelium-dependent vasodilator, leading to a drop in blood pressure. It also causes {{contraction}} of non-vascular smooth muscle in the bronchus and gut, increases vascular permeability and is also involved in the mechanism of pain. Bradykinin also causes <b>natriuresis,</b> contributing to the drop in blood pressure.|$|E
50|$|Fractional {{excretion}} {{of other}} substances {{can be measured}} to determine renal clearance including urea, uric acid, and lithium. These {{can be used in}} patients undergoing diuretic therapy, since diuretics induce a <b>natriuresis.</b> Thus, the urinary sodium concentration and FENa may be higher in patients receiving diuretics in spite of prerenal pathology.|$|E
50|$|Brain natriuretic peptide (BNP) is {{a cardiac}} {{neurohormone}} secreted from ventricular myocytes {{at the end}} of diastole in response to stretching experienced by cardiomyocytes. Elevated levels of BNP indicate excessive <b>natriuresis</b> and decline of ventricular function, especially during diastole. Increased BNP concentrations have been found in patients who experience specifically diastolic heart failure.|$|E
50|$|Nesiritide, a {{recombinant}} form of B-natriuretic peptide, {{is indicated}} {{for use in}} patients with acute decompensated heart failure who have dyspnea at rest. Nesiritide promotes diuresis and <b>natriuresis,</b> thereby ameliorating volume overload. It is thought that, while BNP is elevated in heart failure, the peptide that is produced is actually dysfunctional or non-functional and thereby ineffective.|$|E
50|$|Dopamine receptors {{are present}} along the nephron in the kidney, with {{proximal}} tubule epithelial cells showing the highest density. In rats, D1-like receptors are {{present on the}} juxtaglomerular apparatus and on renal tubules, while D2-like receptors are present on the glomeruli, zona glomerulosa cells of the adrenal cortex, renal tubules, and postganglionic sympathetic nerve terminals. Dopamine signaling affects diuresis and <b>natriuresis.</b>|$|E
50|$|Urodilatin is {{a hormone}} that causes <b>natriuresis</b> through {{increasing}} renal blood flow. It is secreted {{in response to}} increased mean arterial pressure and increased blood volume from {{the cells of the}} distal tubule and collecting duct. It is important in oliguric patients (such as those with acute renal failure and chronic renal failure) as it lowers serum creatinine and increases urine output.|$|E
5000|$|In rats with {{diabetes}} insipidus, thiazide diuretics inhibit the NaCl cotransporter in the renal distal convoluted tubule, leading indirectly to less water and solutes {{being delivered to}} the distal tubule. [...] The impairment of Na transport in the distal convoluted tubule induces <b>natriuresis</b> and water loss, while increasing the reabsorption of calcium in this segment in a manner unrelated to sodium transport.|$|E
50|$|ACE inhibitors {{block the}} {{conversion}} of angiotensin I (AI) to angiotensin II (AII). They thereby lower arteriolar resistance and increase venous capacity; decrease cardiac output, cardiac index, stroke work, and volume; lower resistance in {{blood vessels in the}} kidneys; and lead to increased <b>natriuresis</b> (excretion of sodium in the urine).Renin increases in concentration in the blood as a result of negative feedback of conversion of AI to AII. AI increases for the same reason; AII and aldosterone decrease. Bradykinin increases because of less inactivation by ACE.|$|E
50|$|Hydrochlorothiazide {{belongs to}} thiazide class of diuretics. It reduces blood volume by {{acting on the}} kidneys to reduce sodium (Na+) {{reabsorption}} in the distal convoluted tubule. The major site of action in the nephron appears on an electroneutral NaCl co-transporter by competing for the chloride site on the transporter. By impairing Na+ transport in the distal convoluted tubule, hydrochlorothiazide induces a <b>natriuresis</b> and concomitant water loss. Thiazides increase the reabsorption of calcium in this segment in a manner unrelated to sodium transport. Additionally, by other mechanisms, HCTZ is believed to lower peripheral vascular resistance.|$|E
50|$|ENaC {{is located}} in the apical {{membrane}} of polarized epithelial cells in particular in the kidney (primarily in the distal tubule), the lung, and the colon. Epithelial sodium channels facilitate Na⁺ reabsorption across the apical membranes of epithelia in the distal nephron, respiratory and reproductive tracts and exocrine glands. Since Na⁺ ion concentration is a major determinant of extracellular fluid osmolarity, changes in Na⁺ concentration affect the movement of fluids and consequently fluid volume and blood pressure. The activity of ENaC in the colon and kidney is modulated by the mineralcorticoid aldosterone. It can be blocked by either triamterene or amiloride, which are used medically to serve as diuretics. In the kidney, it is inhibited by atrial natriuretic peptide, causing <b>natriuresis</b> and diuresis.|$|E
50|$|Doses of {{caffeine}} {{equivalent to the}} amount normally found in standard servings of tea, coffee and carbonated soft drinks appear to have no diuretic action. However, acute ingestion {{of caffeine}} in large doses (at least 250-300 mg, equivalent to the amount found in 2-3 cups of coffee or 5-8 cups of tea) results in a short-term stimulation of urine output in individuals who have been deprived of caffeine {{for a period of}} days or weeks. This increase is due to both a diuresis (increase in water excretion) and a <b>natriuresis</b> (increase in saline excretion); it is mediated via proximal tubular adenosine receptor blockade. The acute increase in urinary output may increase the risk of dehydration. However, chronic users of caffeine develop a tolerance to this effect, and experience no increase in urinary output.|$|E
5000|$|... 16α-OHP has {{approximately}} 67% and 43% of the affinity of progesterone for the PR-A and PR-B, respectively, {{and acts}} as an agonist of these receptors similarly to progesterone. It was found to produce <b>natriuresis</b> similar to that produced by spironolactone when administered to humans, suggesting that it also has antimineralocorticoid activity similarly to progesterone. However, surprisingly, 16α-OHP showed low affinity for the mineralocorticoid receptor (MR) of greater than 1 μM (compared to 1 nM for progesterone) and showed no antagonism of the MR at up to a concentration of 1 μM (whereas progesterone shows potent such activity). However, the findings of another study suggested that 16α-OHP antagonizes the effects of aldosterone via the MR, and it may still be possible that 16α-OHP has significant antimineralocorticoid activity in some cells {{in spite of its}} weak MR affinity.|$|E
50|$|Atrial natriuretic peptide (CDD/ANP-99-126) is {{a hormone}} system of {{clinical}} importance. Urodilatin (CDD/ ANP-95-126) is a homologue natriuretic peptide that differs from CDD/ANP-99-126 which is excreted into the circulation via exocytosis. The {{prototype of the}} natriuretic hormones is cardiodilatin/atrial natriuretic peptide (CDD/ANP). The endocrine heart is composed of specific myoendocrine cells that synthesize and secrete the natriuretic peptide hormones which exhibit diuretic, and vasorelaxant properties; secretion {{is the basis for}} a paracrine system regulating water and sodium reabsorption. Research efforts since the early 1980s have studied their effects on electrolyte homeostasis. When administered intravenously, URO induces strong diuresis and <b>natriuresis</b> with tolerable hemodynamic side effects. Urodilatin is localized in the kidney, differentially processed (involved in the regulation of body fluid volume and water-electrolyte excretion, while circulating), and secreted into the urine. As a consequence, urodilatin is involved in drug development along with the prohormone CDD/ANP-1-126 and cardiodilatin CDD/ANP-99-126. A message for the preprohormone is transcribed in the heart and kidneys from the gene of NP type A, resulting in a cGMP-dependent signal transduction which induces diuresis and <b>natriuresis,</b> differentially processed to a peptide of 32 amino acids from the same precursor as renal ANP, may not be identical to the circulating cardiac hormone ANP. The kidneys produce their own natriuretic 32-residue peptide. Urodilatin renal natriuretic peptide potency equals or exceeds that of Atriopeptin ANP-(99-126), the prototype of cardiodilatin. Atriopeptin is only of trivial importance in the regulation of sodium excretion during normal living conditions. Urodilatin is little affected by renal enzymes that inactivate atriopeptin, as the kidney elutes with urodilatin rather than with ANP. The degradation rates of (125I)-urodilatin and 125I-ANP by pure recombinant NEP (rNEP) were compared. Phosphoramidon, a potent inhibitor of NEP, completely protected both peptides from metabolism by rNEP. Urodilatin, has a four-residue extension at the N-terminus neutral endopeptidase-24.11 (NEP) plays a physiological role in metabolizing atrial natriuretic peptide, and C-type natriuretic peptide (prohormone) degraded the bioactive peptides at about half the rate though the C-terminal that compete with natriuretic peptides for hydrolysis by neutral endopeptidase.|$|E
50|$|Progesterone is {{the most}} {{important}} progestogen in the body, the result of its action as a potent agonist of the nuclear progesterone receptor (nPR) (with an affinity of KD = 1 nM). In addition, progesterone is an agonist of the more recently discovered membrane progesterone receptors (mPRs), as well as a ligand of the PGRMC1 (progesterone receptor membrane component 1; formerly known as the σ2 receptor). Moreover, progesterone is also known to be an antagonist of the σ1 receptor, a negative allosteric modulator of the nACh receptors, and a potent antagonist of the mineralocorticoid receptor (MR). Progesterone prevents MR activation by binding to this receptor with an affinity exceeding even those of aldosterone and glucocorticoids such as cortisol and corticosterone, and produces antimineralocorticoid effects, such as <b>natriuresis,</b> at physiological concentrations. In addition, progesterone binds to and behaves as a partial agonist of the glucocorticoid receptor (GR), albeit with very low potency (EC50 >100-fold less relative to cortisol).|$|E
5000|$|His {{obituary}} in The Physiologist journal, and Memoriam in the 11th {{edition of}} his book, are largely verbatim of each other, including as below: Arthur Guyton's research contributions, which include more than 600 papers and 40 books, are legendary and place him among the greatest figures {{in the history of}} cardiovascular physiology. His research covered virtually all areas of cardiovascular regulation and led to many seminal concepts that are now {{an integral part of the}} understanding of cardiovascular disorders such as hypertension, heart failure, and edema. It is difficult to discuss cardiovascular regulation without including his concepts of cardiac output and venous return, negative interstitial fluid pressure and regulation of tissue fluid volume and edema, regulation of tissue blood flow and whole body blood flow auto-regulation, renal-pressure <b>natriuresis,</b> and long-term blood pressure regulation. The Textbook Memoriam continues: [...] "Indeed, his concepts of cardiovascular regulation are found in virtually every major textbook of physiology. They have become so familiar that their origin is sometimes forgotten".|$|E
50|$|Comparable studies, {{in which}} blood pressure, {{heart rate and}} serum {{prolactin}} levels were measured after the administration of 0.5-4 μg/kg/min of epinine by i.v. infusion over a 15-minute period to healthy humans, were reported subsequently by Daul and co-workers. These investigators found that at lower doses (0.5 or 1.0 μg/kg/min), which produced plasma concentrations of 20-80 nM/L, epinine, in common with dopamine, caused a fall in prolactin level, but did not affect blood pressure or heart rate. At higher doses (2.0 or 4.0 μg/kg/min), epinine significantly increased both systolic and diastolic blood pressure, as well as heart rate. In contrast, dopamine caused an increase in systolic blood pressure and heart rate only.Both drugs increased diuresis and <b>natriuresis</b> - effects that {{are thought to be}} due to the activation of renal D1 receptors.It was concluded that at the lower doses, epinine and dopamine exerted their effects only at DA (D2) receptors, but did not activate α- or β-adrenoceptors. At the higher doses, epinine activated α-, β1- and β2-receptors to about the same extent, whereas dopamine showed only a mild stimulation of β1-receptors, without any effects on α- or β2-receptors. Additionally, it was observed that the effects of epinine were largely due to its direct action on receptors, while dopamine also produced some of its effects indirectly, by stimulating norepinephrine release.|$|E
40|$|In {{all forms}} of chronic hypertension, the renal-pressure <b>natriuresis</b> {{mechanism}} is abnormal because sodium excretion {{is the same as}} in normotension despite the increased blood pressure. However, the importance of this resetting of pressure <b>natriuresis</b> as a cause of hypertension is controversial. Theoretically, a resetting of pressure <b>natriuresis</b> could necessitate increased blood pressure to maintain sodium balance or it could occur secondarily to hypertension. Recent studies indicate that, in several models of experimental hypertension (including angiotensin II, aldosterone, adrenocorticotrophic hormone, and norepinephrine hypertension), a primary shift of renal-pressure <b>natriuresis</b> necessitates increased arterial pressure to maintain sodium and water balance. In genetic animal models of hypertension, there also appears to be a resetting of pressure <b>natriuresis</b> before the development of hypertension. Likewise, essential hypertensive patients exhibit abnormal pressure <b>natriuresis,</b> although the precise cause of this defect is not clear. It is likely that multiple renal defects contribute to resetting of pressure <b>natriuresis</b> in essential hypertensive patients. With long-standing hyper-tension, pathological changes that occur secondary to hypertension must also be considered. By analyzing the characteristics of pressure <b>natriuresis</b> in hypertensive patients and by comparin...|$|E
